Alexander E. Perl

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Patrick S. Ward, Jay Patel, David R. Wise et al. · Cancer Cell · 2010 · 2K citations · Full text

Somatic Variant, Biochemistry, Medicine +10

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 734 citations

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +10

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes et al. · The Lancet Oncology · 2017 · 484 citations · Full text

Selective Inhibition, Hematological Malignancy, Oncology +6

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · The Lancet Oncology · 2019 · 465 citations

Hematological Malignancy, Medicine, Hematology +5